Open AccessVolumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutantIDHglioma patients
Author(s) -
Kourosh JafariKhouzani,
Franziska Loebel,
Wolfgang Bogner,
Otto Rapalino,
Gilberto Gonzalez,
Elizabeth R. Gerstner,
S. Andrew,
Tracy T. Batchelor,
Bruce R. Rosen,
Jan Unkelbach,
Helen A. Shih,
Daniel P. Cahill,
Ovidiu C. Andronesi
Publication year - 2016
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/now100
Subject(s) - fluid attenuated inversion recovery , nuclear medicine , hyperintensity , magnetic resonance imaging , glioma , isocitrate dehydrogenase , medicine , radiology , nuclear magnetic resonance , physics , cancer research , enzyme
Gliomas with mutant isocitrate dehydrogenase (IDH) produce high levels of 2-hydroxyglutarate (2HG) that can be quantitatively measured by 3D magnetic resonance spectroscopic imaging (MRSI). Current glioma MRI primarily relies upon fluid-attenuated inversion recovery (FLAIR) hyperintensity for treatment planning, although this lacks specificity for tumor cells. Here, we investigated the relationship between 2HG and FLAIR in mutant IDH glioma patients to determine whether 2HG mapping is valuable for radiotherapy planning.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom